Abstract Cytochrome P450 2C19 (CYP2C19) is the main (or partial) cause for large
differences in the pharmacokinetics of a number of clinically important drugs. On the basis of …

The success of in vitro derived K i values for predicting drug-drug interactions in vivo has
been mixed. For example, the use of hepatic input concentration of inhibitor has resolved the …

Many undesired side effects or therapeutic failures of drugs are the result of differences or
changes in drug metabolism, primarily depending on the levels and activities of cytochrome …

Cytochrome P450 reaction phenotyping to determine the fraction of metabolism (fm) values
for individual enzymes is a standard study in the evaluation of a new drug. However, there …

Variability in drug response can be attributed in part to variability in the activity of drug–
metabolizing enzymes. One of the most important drugmetabolizing enzyme systems in …

We investigated whether CYP2D6 extensive metabolizers carrying a nonfunctional allele
are at higher risk of phenoconversion to poor metabolizers in the presence of CYP2D6 …

Highlights•The interindividual variability of CYP2C members and its impact in drug
metabolism are reviewed.•Current advances in molecular modeling of CYP2C …

Genetic variation of drug-metabolizing enzymes has been recognized as one of the major
causes of the interindividual variability in drug responses. The S-mephenytoin 4 …

This study aimed to develop a joint population pharmacokinetic model for an antipsychotic
agent in development (S33138) and its active metabolite (S35424) produced by reversible …

Interindividual variability in xenobiotic metabolism and drug response is extensive. Genetic
factors are predicted to account for 15–30% of this variability in general, but for certain drugs …